Efficacy of Subsequent Treatments in Patients With HR+ Advanced Breast Cancer Who Progressed on CDK4/6 Inhibitors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
BMC Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
BMC Cancer 2023 Feb 10;23(xx)136, C Karacin, B Oksuzoglu, A Demirci, M Keskinkılıç, NK Baytemür, F Yılmaz, O Selvi, D Erdem, E Avşar, N Paksoy, N Demir, SS Göksu, S Türker, E Bayram, A Çelebi, H Yılmaz, ÖF Kuzu, S Kahraman, İ Gökmen, A Sakin, A Alkan, E Nayır, M Uğraklı, Ö Acar, İ Ertürk, H Demir, F Aslan, Ö Sönmez, T Korkmaz, ÖM Celayir, İ Karadağ, E Kayıkçıoğlu, T Şakalar, İN Öktem, T Eren, E Erul, EE Mocan, Z Kalkan, N Yıldırım, Y Ergün, B Akagündüz, S Karakaya, E Kut, F Teker, BÇ Demirel, K Karaboyun, E Almuradova, OÜ Ünal, A Oyman, D Işık, K Okutur, B Öztosun, BB Gülbağcı, ME Kalender, E Şahin, M Seyyar, Ö Özdemir, F Selçukbiricik, M Kanıtez, İ Dede, M Gümüş, E Gökmen, A Yaren, S Menekşe, S Ebinç, S Aksoy, Gİ İmamoğlu, M Altınbaş, B Çetin, BO Uluç, Ö Er, N Karadurmuş, AP Erdoğan, M Artaç, Ö Tanrıverdi, İ Çiçin, MAN Şendur, E Oktay, İV Bayoğlu, S Paydaş, A Aydıner, DK Salim, Ç Geredeli, T Yavuzşen, M Doğan, İ HacıbekiroğluFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.